Mallinckrodt Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mallinckrodt Plc (MNKKQ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Mallinckrodt Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,979M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-0.8% annualized vs trailing 12 months).
- Peer revenue share: Mallinckrodt Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNKKQ Sales vs. its Competitors, 2022
Mallinckrodt Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -12.0% for Mallinckrodt Plc. Mallinckrodt Plc's share of combined industry revenue moved from 0.12% to 0.10%, a loss of 0.02 percentage points.
Mallinckrodt Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mallinckrodt Plc | No | No | No | No |
| High-Confidence Competitors (3) | - | - | - | |
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNKKQ Stock Performance relative to its Competitors
MNKKQ Stock Performance relative to High-Confidence Competitors
MNKKQ Stock Performance relative to Similar Growth & Profitability Competitors
Mallinckrodt Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ovid Therapeutics Inc | Named by the company | 85% |
| Trevena inc | Named by the company | 85% |
| Nu med Plus Inc | Named by the company | 85% |
| Indivior Pharmaceuticals Inc | Named by the company | 85% |
| Abbvie Inc | Named by the company | 85% |
| Endo International Plc | Named by the company | 85% |
| Collegium Pharmaceutical Inc | Named by the company | 85% |
| Viatris Inc | Named by the company | 85% |
| Amneal Pharmaceuticals Inc | Named by the company | 85% |
| Eton Pharmaceuticals Inc | Named by the company | 85% |
| Eagle Pharmaceuticals inc | Named by the company | 85% |
| Perrigo Company Plc | Named by the company | 85% |
| Bausch Health Companies Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Mallinckrodt Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.